| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443794 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
The treatment with bevacizumab, cetuximab and panitumumab is mainly considered to be not cost-effective in patients with mCRC. However, testing for Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or panitumumab is found to be clearly cost-effective compared to no testing. Future research should focus on the CE of first-line treatment with cetuximab or panitumumab and studies on upcoming agents like regorafenib and aflibercept.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A. Lange, A. Prenzler, M. Frank, M. Kirstein, A. Vogel, J.M. von der Schulenburg,